Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer
LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer. By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously r...Active Biotech's I-3D Micro-dosing Clinical Trial Concluded
...eted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds tasq for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperati...New Positive Pre-clinical Data for Active Biotech's RA Project I-3D
...eted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds tasq for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation wi...New Report Just Published: World Prostate Cancer Therapeutics Market Report
...atients II-59 Panacea Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer Detection II-60 Active Biotech Reveals Results of tasq Phase I Study for Prostate Cancer II-61 Positive Results of Combined Hormone and Radiation Therapies in Locally Advanced Prostate Cancer I...